Merck KGaA reduced its outlook for sales and profit growth this year, citing the impact of a weak US dollar and uncertainty ...

The German life-sciences and electronics company slashed its full-year guidance on the back of challenging macroeconomic ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Oracle Corp. (ORCL), IBM Corp. (IBM) ...

Merck & Co., Inc. operates as a healthcare company worldwide. Based in Rahway, the company has 73,000 full time employees and ...

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by ...

Janux Therapeutics, Inc.’s JANX share price has dipped by 7.22%, which has investors questioning if this is right time to buy ...

Merck is facing an awkward encore as one of the worst-performing blue chip stocks in 2025, sliding 23.3% year-to-date.

We recently published a list of 10 Worst Blue Chip Stocks to Buy. In this article, we are going to take a look at where Merck ...

Merck is shelling out $895 million to beef up its De Soto, Kansas facility, giving its Animal Health division a mighty boost. This project aims to generate 2,500 construction jobs and launch ...

C4 Therapeutics, Inc.’s CCCC share price has surged by 12.77%, which has investors questioning if this is right time to sell.

Merck’s stock was gaining after the drugmaker beat quarterly earnings expectations again and maintained its full-year outlook despite additional costs related to tariffs. Photo: Getty Images ...

To make the world smarter, happier, and richer. Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches ...